Table 4.
siRNA therapeutic applications in spinal cord injury.
| Gene target(s) | Delivery system | Mode(s) | Effect(s) | References |
|---|---|---|---|---|
| GFAP | adenovirus vectors |
In vitro: C6 glioma cells In vivo: SCI model rat |
-Improvement of urinary function | [112]* |
| Vimentin | ||||
| EphB3 | Lentiviral vector |
In vivo: female Wistar rats |
-Improvement in axonal regeneration and the motor function | [114]* |
| iNOS | chitosan |
In vivo: Female BALB/c mice1 |
-Improvement of the secondary damage following SCI | [121]* |
| Nischarin | PEI-ALG |
In vivo: SCI model rat |
-Improvement of motor function | [124]* |
| RhoA | 2’O-methylated siRNA |
In vivo: female Sprague- Dawley rats |
-Improvement in walking -declining of allodynia |
[170] |
*Explained in the text